{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:03:38Z","timestamp":1781103818136,"version":"3.54.1"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11596-024-2936-5","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T02:16:03Z","timestamp":1734315363000},"page":"1155-1174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene Therapy Insights"],"prefix":"10.1007","volume":"44","author":[{"given":"Disha D.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul R.","family":"Chorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aanshi J.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirjari","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupendra G.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyajeet S.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"5","key":"2936_CR1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","volume":"109","author":"K De Boeck","year":"2020","unstructured":"De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr, 2020,109(5):893\u2013899","journal-title":"Acta Paediatr"},{"issue":"3","key":"2936_CR2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ame2.12180","volume":"4","author":"Q Chen","year":"2021","unstructured":"Chen Q, Shen Y, Zheng J. A review of cystic fibrosis: Basic and clinical aspects. Animal Model Exp Med, 2021,4(3):220\u2013232","journal-title":"Animal Model Exp Med"},{"issue":"10059","key":"2936_CR3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS. Cystic fibrosis. Lancet, 2016,388(10059):2519\u20132531","journal-title":"Lancet"},{"key":"2936_CR4","doi-asserted-by":"crossref","first-page":"190021","DOI":"10.1183\/16000617.0021-2019","volume":"28","author":"V Somogyi","year":"2019","unstructured":"Somogyi V, Chaudhuri N, Torrisi SE, et al. The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev, 2019,28:190021","journal-title":"Eur Respir Rev"},{"issue":"5","key":"2936_CR5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcf.2020.11.006","volume":"20","author":"J Barben","year":"2021","unstructured":"Barben J, Castellani C, Munck A, et al. Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome\/cystic fibrosis screen positive, inconclusive diagnosis (CRMS\/CFSPID). J Cyst Fibros, 2021,20(5):810\u2013819","journal-title":"J Cyst Fibros"},{"issue":"1","key":"2936_CR6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.chest.2018.07.025","volume":"155","author":"CS King","year":"2019","unstructured":"King CS, Brown AW, Aryal S, et al. Critical Care of the Adult Patient With Cystic Fibrosis. Chest, 2019,155(1):202\u2013214","journal-title":"Chest"},{"issue":"1","key":"2936_CR7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bjpt.2016.12.001","volume":"21","author":"F D\u2019Abrosca","year":"2017","unstructured":"D\u2019Abrosca F, Garabelli B, Savio G, et al. Comparing airways clearance techniques in chronic obstructive pulmonary disease and bronchiectasis: positive expiratory pressure or temporary positive expiratory pressure? A retrospective study. Braz J Phys Ther, 2017,21(1):15\u201323","journal-title":"Braz J Phys Ther"},{"key":"2936_CR8","unstructured":"Dwyer T. Huff and puff of exercise for airway clearance in cystic fibrosis: how clear is the evidence? Thorax, 2021,Apr 29:thoraxjnl-2020-216622"},{"key":"2936_CR9","first-page":"73","volume":"25","author":"LM Schofield","year":"2018","unstructured":"Schofield LM, Duff A, Brennan C. Airway Clearance Techniques for Primary Ciliary Dyskinesia; is the Cystic Fibrosis literature portable? Paediatr Respir Rev, 2018,25:73\u201377","journal-title":"Paediatr Respir Rev"},{"issue":"8","key":"2936_CR10","first-page":"CD008319","volume":"8","author":"S Smith","year":"2022","unstructured":"Smith S, Rowbotham NJ, Charbek E. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev, 2022,8(8):CD008319","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2936_CR11","first-page":"684","volume":"109","author":"J Calvo-Lerma","year":"2017","unstructured":"Calvo-Lerma J, Mart\u00ednez-Barona S, Masip E, et al. Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption. Rev Esp Enferm Dig, 2017,109(10):684\u2013689","journal-title":"Rev Esp Enferm Dig"},{"issue":"Suppl2","key":"2936_CR12","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2017.06.007","volume":"16","author":"M Sathe","year":"2017","unstructured":"Sathe M, Houwen R. Meconium ileus in Cystic Fibrosis. J Cyst Fibros, 2017,16 Suppl 2:S32\u2013S39","journal-title":"J Cyst Fibros"},{"issue":"2","key":"2936_CR13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/joim.12314","volume":"277","author":"MD Amaral","year":"2015","unstructured":"Amaral MD. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients. J Intern Med, 2015,277(2):155\u2013166","journal-title":"J Intern Med"},{"issue":"7","key":"2936_CR14","first-page":"721","volume":"28","author":"S Smith","year":"2022","unstructured":"Smith S, Borchardt M. Analyzing the use and impact of elexacaftor\/tezacaftor\/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population. J Manag Care Spec Pharm, 2022,28(7):721\u2013731","journal-title":"J Manag Care Spec Pharm"},{"key":"2936_CR15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coph.2021.01.001","volume":"57","author":"A Gramegna","year":"2021","unstructured":"Gramegna A, Contarini M, Bindo F, Aliberti S, Blasi F. Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation. Curr Opin Pharmacol, 2021,57:81\u201388","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"2936_CR16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jcf.2010.03.001","volume":"9","author":"M Ulrich","year":"2010","unstructured":"Ulrich M, Worlitzsch D, Viglio S, et al. Alveolar inflammation in cystic fibrosis. J Cyst Fibros, 2010,9(3):217\u2013227","journal-title":"J Cyst Fibros"},{"issue":"12","key":"2936_CR17","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/CM9.0000000000000839","volume":"133","author":"JY Chen","year":"2020","unstructured":"Chen JY, Qiao K, Liu F, et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis. Chin Med J (Engl), 2020,133(12):1390\u20131396","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"2936_CR18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jcf.2017.06.008","volume":"16","author":"G Snell","year":"2017","unstructured":"Snell G, Reed A, Stern M, et al. The evolution of lung transplantation for cystic fibrosis: A 2017 update. J Cyst Fibros, 2017,16(5):553\u2013564","journal-title":"J Cyst Fibros"},{"issue":"4","key":"2936_CR19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/14728214.2010.517746","volume":"15","author":"H Grasemann","year":"2010","unstructured":"Grasemann H, Ratjen F. Emerging therapies for cystic fibrosis lung disease. Expert Opin Emerg Drugs, 2010,15(4):653\u2013659","journal-title":"Expert Opin Emerg Drugs"},{"key":"2936_CR20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21037\/sci.2019.06.09","volume":"6","author":"Q Lu","year":"2019","unstructured":"Lu Q, El-Hashash AHK. Cell-based therapy for idiopathic pulmonary fibrosis. Stem Cell Investig, 2019,6:22","journal-title":"Stem Cell Investig"},{"issue":"8","key":"2936_CR21","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3642","volume":"20","author":"DN Kotton","year":"2014","unstructured":"Kotton DN, Morrisey EE. Lung regeneration: mechanisms, applications and emerging stem cell populations. Nat Med, 2014,20(8):822\u2013832","journal-title":"Nat Med"},{"issue":"7","key":"2936_CR22","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/03639045.2017.1298122","volume":"43","author":"I Villate-Beitia","year":"2017","unstructured":"Villate-Beitia I, Zarate J, Puras G, et al. Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis. Drug Dev Ind Pharm, 2017,43(7):1071\u20131081","journal-title":"Drug Dev Ind Pharm"},{"issue":"2S","key":"2936_CR23","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.jcf.2017.09.005","volume":"17","author":"DM Cholon","year":"2018","unstructured":"Cholon DM, Gentzsch M. Recent progress in translational cystic fibrosis research using precision medicine strategies. J Cyst Fibros, 2018,17(2S):S52\u2013S60","journal-title":"J Cyst Fibros"},{"key":"2936_CR24","doi-asserted-by":"crossref","first-page":"i859","DOI":"10.1136\/bmj.i859","volume":"352","author":"BS Quon","year":"2016","unstructured":"Quon BS, Rowe SM. New and emerging targeted therapies for cystic fibrosis. BMJ, 2016,352:i859","journal-title":"BMJ"},{"issue":"1","key":"2936_CR25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1073\/pnas.0406266102","volume":"102","author":"G Wang","year":"2005","unstructured":"Wang G, Bunnell BA, Painter RG, et al. Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc Natl Acad Sci U S A, 2005,102(1):186\u2013191","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2936_CR26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12967-021-03099-4","volume":"19","author":"JA Lee","year":"2021","unstructured":"Lee JA, Cho A, Huang EN, et al. Gene therapy for cystic fibrosis: new tools for precision medicine. J Transl Med, 2021,19(1):452","journal-title":"J Transl Med"},{"key":"2936_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2019.00121","volume":"10","author":"I Pranke","year":"2019","unstructured":"Pranke I, Golec A, Hinzpeter A, et al. Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine. Front Pharmacol, 2019,10:121","journal-title":"Front Pharmacol"},{"key":"2936_CR28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.omtm.2021.02.020","volume":"21","author":"LI Marquez Loza","year":"2021","unstructured":"Marquez Loza LI, Cooney AL, Dong Q, et al. Increased CFTR expression and function from an optimized lentiviral vector for cystic fibrosis gene therapy. Mol Ther Methods Clin Dev, 2021,21:94\u2013106","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"2936_CR29","doi-asserted-by":"crossref","first-page":"L341","DOI":"10.1152\/ajplung.00113.2022","volume":"323","author":"L Ikonomou","year":"2022","unstructured":"Ikonomou L, Magnusson M, Dries R, et al. Stem cells, cell therapies, and bioengineering in lung biology and disease 2021. Am J Physiol Lung Cell Mol Physiol, 2022,323(3):L341\u2013L354","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"6","key":"2936_CR30","first-page":"672","volume":"21","author":"A Ebrahimi","year":"2021","unstructured":"Ebrahimi A, Ahmadi H, Pourfraidon Ghasrodashti Z, et al. Therapeutic effects of stem cells in different body systems, a novel method that is yet to gain trust: A comprehensive review. Bosn J Basic Med Sci, 2021,21(6):672\u2013701","journal-title":"Bosn J Basic Med Sci"},{"issue":"2","key":"2936_CR31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41401-022-00952-0","volume":"44","author":"L Qin","year":"2023","unstructured":"Qin L, Liu N, Bao CL, et al. Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin. Acta Pharmacol Sin, 2023,44(2):268\u2013287","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"2936_CR32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4236\/scd.2013.32019","volume":"3","author":"TL Bonfield","year":"2013","unstructured":"Bonfield TL, Lennon D, Ghosh SK, DiMarino AM, Weinberg A, Caplan AI. Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease. Stem Cell Discovery, 2013,3(2):139\u2013153","journal-title":"Stem Cell Discovery"},{"key":"2936_CR33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fphar.2019.00074","volume":"10","author":"A Berical","year":"2019","unstructured":"Berical A, Lee RE, Randell SH, et al. Challenges Facing Airway Epithelial Cell-Based Therapy for Cystic Fibrosis. Front Pharmacol, 2019,10:74","journal-title":"Front Pharmacol"},{"issue":"2","key":"2936_CR34","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/cr1001832","volume":"111","author":"M Mahmoudi","year":"2011","unstructured":"Mahmoudi M, Hosseinkhani H, Hosseinkhani M, et al. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem Rev, 2011,111(2):253\u2013280","journal-title":"Chem Rev"},{"issue":"1","key":"2936_CR35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13287-023-03448-8","volume":"14","author":"AS Iltis","year":"2023","unstructured":"Iltis AS, Koster G, Reeves E, et al. Ethical, legal, regulatory, and policy issues concerning embryoids: a systematic review of the literature. Stem Cell Res Ther, 2023,14(1):209","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"2936_CR36","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1177\/0192623320918241","volume":"49","author":"R Haworth","year":"2021","unstructured":"Haworth R, Sharpe M. Accept or Reject: The Role of Immune Tolerance in the Development of Stem Cell Therapies and Possible Future Approaches. Toxicol Pathol, 2021,49(7):1308\u20131316","journal-title":"Toxicol Pathol"},{"issue":"4","key":"2936_CR37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.stem.2012.01.018","volume":"10","author":"H Mou","year":"2012","unstructured":"Mou H, Zhao R, Sherwood R, et al. Generation of multipotent lung and airway progenitors from mouse ESCs and patient-specific cystic fibrosis iPSCs. Cell Stem Cell, 2012,10(4):385\u2013397","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2936_CR38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.stem.2020.09.017","volume":"28","author":"FJ Hawkins","year":"2021","unstructured":"Hawkins FJ, Suzuki S, Beermann ML, et al. Derivation of Airway Basal Stem Cells from Human Pluripotent Stem Cells. Cell Stem Cell, 2021,28(1):79\u201395.e8","journal-title":"Cell Stem Cell"},{"key":"2936_CR39","doi-asserted-by":"crossref","unstructured":"Ajilore PO, Yang HY, Kerasidis A, et al. Curative Measures for Cystic Fibrosis: A Perspective on Current Stem Cell-Based, Gene, and Small Molecule Therapies. Georgetown Medical Review, 2022,6(1)","DOI":"10.52504\/001c.38728"},{"issue":"4","key":"2936_CR40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41551-023-01133-y","volume":"8","author":"J Harding","year":"2024","unstructured":"Harding J, Vintersten-Nagy K, Yang H, et al. Immune-privileged tissues formed from immunologically cloaked mouse embryonic stem cells survive long term in allogeneic hosts. Nat Biomed Eng, 2024,8(4):427\u2013442","journal-title":"Nat Biomed Eng"},{"issue":"8","key":"2936_CR41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4252\/wjsc.v11.i8.491","volume":"11","author":"LVF Pess\u00f4a","year":"2019","unstructured":"Pess\u00f4a LVF, Bressan FF, Freude KK. Induced pluripotent stem cells throughout the animal kingdom: Availability and applications. World J Stem Cells, 2019,11(8):491\u2013505","journal-title":"World J Stem Cells"},{"issue":"7","key":"2936_CR42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4252\/wjsc.v11.i7.421","volume":"11","author":"J Bragan\u00e7a","year":"2019","unstructured":"Bragan\u00e7a J, Lopes JA, Mendes-Silva L, et al. Induced pluripotent stem cells, a giant leap for mankind therapeutic applications. World J Stem Cells, 2019,11(7):421\u2013430","journal-title":"World J Stem Cells"},{"key":"2936_CR43","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/ncomms2550","volume":"4","author":"A Filareto","year":"2013","unstructured":"Filareto A, Parker S, Darabi R, et al. An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat Commun, 2013,4:1549","journal-title":"Nat Commun"},{"issue":"1","key":"2936_CR44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3727\/096368910X","volume":"20","author":"DC Ding","year":"2011","unstructured":"Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant, 2011,20(1):5\u201314","journal-title":"Cell Transplant"},{"issue":"6","key":"2936_CR45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/bioengineering10060728","volume":"10","author":"AI Nyk\u00e4nen","year":"2023","unstructured":"Nyk\u00e4nen AI, Liu M, Keshavjee S. Mesenchymal Stromal Cell Therapy in Lung Transplantation. Bioengineering (Basel), 2023,10(6):728","journal-title":"Bioengineering (Basel)"},{"issue":"1","key":"2936_CR46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17476348.2020.1679628","volume":"14","author":"FF Cruz","year":"2020","unstructured":"Cruz FF, Rocco PRM. The potential of mesenchymal stem cell therapy for chronic lung disease. Expert Rev Respir Med, 2020,14(1):31\u201339","journal-title":"Expert Rev Respir Med"},{"key":"2936_CR47","volume-title":"StatPearls","author":"K Khaddour","year":"2024","unstructured":"Khaddour K, Hana CK, Mewawalla P. Hematopoietic Stem Cell Transplantation. [Updated 2023 May 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK536951\/"},{"issue":"3","key":"2936_CR48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/cells11030557","volume":"11","author":"I Rao","year":"2022","unstructured":"Rao I, Crisafulli L, Paulis M, et al. Hematopoietic Cells from Pluripotent Stem Cells: Hope and Promise for the Treatment of Inherited Blood Disorders. Cells, 2022,11(3):557","journal-title":"Cells"},{"issue":"2","key":"2936_CR49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tips.2020.11.008","volume":"42","author":"LM Bush","year":"2021","unstructured":"Bush LM, Healy CP, Javdan SB, et al. Biological Cells as Therapeutic Delivery Vehicles. Trends Pharmacol Sci, 2021,42(2):106\u2013118","journal-title":"Trends Pharmacol Sci"},{"issue":"17\u201318","key":"2936_CR50","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1089\/hum.2020.160","volume":"31","author":"NE King","year":"2020","unstructured":"King NE, Suzuki S, Barill\u00e0 C, et al. Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis. Hum Gene Ther, 2020,31(17\u201318):956\u2013972","journal-title":"Hum Gene Ther"},{"key":"2936_CR51","doi-asserted-by":"crossref","unstructured":"Conrad C, Magnen M, Tsui J, et al. Decoding functional hematopoietic progenitor cells in the adult human lung. Preprint. Res Sq, 2024,rs.3.rs-3576483","DOI":"10.21203\/rs.3.rs-3576483\/v2"},{"issue":"1","key":"2936_CR52","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s13287-022-03181-8","volume":"13","author":"W Cheng","year":"2022","unstructured":"Cheng W, Zeng Y, Wang D. Stem cell-based therapy for pulmonary fibrosis. Stem Cell Res Ther, 2022,13(1):492","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"2936_CR53","doi-asserted-by":"crossref","first-page":"1785161","DOI":"10.1080\/20013078.2020.1785161","volume":"9","author":"K Popowski","year":"2020","unstructured":"Popowski K, Lutz H, Hu S, et al. Exosome therapeutics for lung regenerative medicine. J Extracell Vesicles, 2020,9(1):1785161","journal-title":"J Extracell Vesicles"},{"issue":"2","key":"2936_CR54","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00204-021-03188-9","volume":"96","author":"A Masui","year":"2022","unstructured":"Masui A, Hirai T, Gotoh S. Perspectives of future lung toxicology studies using human pluripotent stem cells. Arch Toxicol, 2022,96(2):389\u2013402","journal-title":"Arch Toxicol"},{"issue":"1","key":"2936_CR55","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s13287-022-03041-5","volume":"13","author":"P Liu","year":"2022","unstructured":"Liu P, Mao Y, Xie Y, et al. Stem cells for treatment of liver fibrosis\/cirrhosis: clinical progress and therapeutic potential. Stem Cell Res Ther, 2022,13(1):356","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"2936_CR56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-9440(10)63147-1","volume":"164","author":"KU Hong","year":"2004","unstructured":"Hong KU, Reynolds SD, Watkins S, et al. Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. Am J Pathol, 2004,164(2):577\u2013588","journal-title":"Am J Pathol"},{"issue":"1","key":"2936_CR57","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13287-022-02737-y","volume":"13","author":"T Xie","year":"2022","unstructured":"Xie T, Lynn H, Parks WC, et al. Abnormal respiratory progenitors in fibrotic lung injury. Stem Cell Res Ther, 2022,13(1):64","journal-title":"Stem Cell Res Ther"},{"issue":"9\u201310","key":"2936_CR58","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1242\/dmm.006031","volume":"3","author":"JR Rock","year":"2010","unstructured":"Rock JR, Randell SH, Hogan BL. Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling. Dis Model Mech, 2010,3(9\u201310):545\u2013556","journal-title":"Dis Model Mech"},{"issue":"3","key":"2936_CR59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1089\/ars.2020.8190","volume":"35","author":"D Klein","year":"2021","unstructured":"Klein D. Lung Multipotent Stem Cells of Mesenchymal Nature: Cellular Basis, Clinical Relevance, and Implications for Stem Cell Therapy. Antioxid Redox Signal, 2021,35(3):204\u2013216","journal-title":"Antioxid Redox Signal"},{"key":"2936_CR60","doi-asserted-by":"crossref","first-page":"645858","DOI":"10.3389\/fphar.2021.645858","volume":"12","author":"SM Busch","year":"2021","unstructured":"Busch SM, Lorenzana Z, Ryan AL. Implications for Extracellular Matrix Interactions With Human Lung Basal Stem Cells in Lung Development, Disease, and Airway Modeling. Front Pharmacol, 2021,12:645858","journal-title":"Front Pharmacol"},{"key":"2936_CR61","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.2147\/JIR.S318327","volume":"14","author":"S Yang","year":"2021","unstructured":"Yang S, Yu M. Role of Goblet Cells in Intestinal Barrier and Mucosal Immunity. J Inflamm Res, 2021,14:3171\u20133183","journal-title":"J Inflamm Res"},{"issue":"9","key":"2936_CR62","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.3390\/cells9092090","volume":"9","author":"P Scudieri","year":"2020","unstructured":"Scudieri P, Musante I, Venturini A, et al. Ionocytes and CFTR Chloride Channel Expression in Normal and Cystic Fibrosis Nasal and Bronchial Epithelial Cells. Cells, 2020;9(9):2090","journal-title":"Cells"},{"issue":"7980","key":"2936_CR63","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41586-023-06549-9","volume":"621","author":"F Yuan","year":"2023","unstructured":"Yuan F, Gasser GN, Lemire E, et al. Transgenic ferret models define pulmonary ionocyte diversity and function. Nature, 2023,621(7980):857\u2013867","journal-title":"Nature"},{"issue":"8","key":"2936_CR64","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm.3653","volume":"20","author":"SJ Forbes","year":"2014","unstructured":"Forbes SJ, Rosenthal N. Preparing the ground for tissue regeneration: from mechanism to therapy. Nat Med, 2014,20(8):857\u2013869","journal-title":"Nat Med"},{"issue":"3","key":"2936_CR65","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/term.1746","volume":"9","author":"SV Murphy","year":"2015","unstructured":"Murphy SV, Atala A. Cell therapy for cystic fibrosis. J Tissue Eng Regen Med, 2015,9(3):210\u2013223","journal-title":"J Tissue Eng Regen Med"},{"issue":"60","key":"2936_CR66","doi-asserted-by":"crossref","first-page":"102600","DOI":"10.18632\/oncotarget.18126","volume":"8","author":"X Li","year":"2017","unstructured":"Li X, Yue S, Luo Z. Mesenchymal stem cells in idiopathic pulmonary fibrosis. Oncotarget, 2017,8(60):102600\u2013102616","journal-title":"Oncotarget"},{"issue":"8","key":"2936_CR67","doi-asserted-by":"crossref","first-page":"e69299","DOI":"10.1371\/journal.pone.0069299","volume":"8","author":"Y Moodley","year":"2013","unstructured":"Moodley Y, Vaghjiani V, Chan J, et al. Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study. PLoS One, 2013,8(8):e69299","journal-title":"PLoS One"},{"key":"2936_CR68","doi-asserted-by":"crossref","first-page":"663203","DOI":"10.3389\/fimmu.2021.663203","volume":"12","author":"C van Geffen","year":"2021","unstructured":"van Geffen C, Dei\u00dfler A, Quante M, et al. Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes? Front Immunol, 2021,12:663203","journal-title":"Front Immunol"},{"issue":"23","key":"2936_CR69","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.3390\/ijms222313009","volume":"22","author":"XD Tang","year":"2021","unstructured":"Tang XD, Ji TT, Dong JR, et al. Pathogenesis and Treatment of Cytokine Storm Induced by Infectious Diseases. Int J Mol Sci, 2021,22(23):13009","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2936_CR70","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s13287-021-02574-5","volume":"12","author":"S Takao","year":"2021","unstructured":"Takao S, Nakashima T, Masuda T, et al. Human bone marrow-derived mesenchymal stromal cells cultured in serumfree media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther, 2021,12(1):506","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"2936_CR71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/sctm.19-0092","volume":"9","author":"L Chow","year":"2020","unstructured":"Chow L, Johnson V, Impastato R, et al. Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells. Stem Cells Transl Med, 2020,9(2):235\u2013249","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"2936_CR72","doi-asserted-by":"crossref","first-page":"fuad029","DOI":"10.1093\/femsre\/fuad029","volume":"47","author":"E Santos-Fernandez","year":"2023","unstructured":"Santos-Fernandez E, Martin-Souto L, Antoran A, et al. Microbiota and fungal-bacterial interactions in the cystic fibrosis lung. FEMS Microbiol Rev, 2023,47(3):fuad029","journal-title":"FEMS Microbiol Rev"},{"issue":"8","key":"2936_CR73","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1164\/rccm.201001-0010OC","volume":"182","author":"SH Mei","year":"2010","unstructured":"Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med, 2010,182(8):1047\u20131057","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2936_CR74","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5582\/bst.2019.01226","volume":"13","author":"J Xia","year":"2019","unstructured":"Xia J, Minamino S, Kuwabara K, et al. Stem cell secretome as a new booster for regenerative medicine. Biosci Trends, 2019,13(4):299\u2013307","journal-title":"Biosci Trends"},{"issue":"5","key":"2936_CR75","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jcyt.2018.11.012","volume":"21","author":"Y Shi","year":"2019","unstructured":"Shi Y, Shi H, Nomi A, et al. Mesenchymal stem cell-derived extracellular vesicles: a new impetus of promoting angiogenesis in tissue regeneration. Cytotherapy, 2019,21(5):497\u2013508","journal-title":"Cytotherapy"},{"issue":"1","key":"2936_CR76","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13287-020-01648-0","volume":"11","author":"LC Liew","year":"2020","unstructured":"Liew LC, Ho BX, Soh BS. Mending a broken heart: current strategies and limitations of cell-based therapy. Stem Cell Res Ther, 2020,11(1):138","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"2936_CR77","first-page":"1068","volume":"11","author":"J Wi\u015bniewska","year":"2021","unstructured":"Wi\u015bniewska J, Sadowska A, W\u00f3jtowicz A, et al. Perspective on Stem Cell Therapy in Organ Fibrosis: Animal Models and Human Studies. Life (Basel), 2021,11(10):1068","journal-title":"Life (Basel)"},{"key":"2936_CR78","doi-asserted-by":"crossref","first-page":"634566","DOI":"10.3389\/fped.2021.634566","volume":"9","author":"MS Zinter","year":"2021","unstructured":"Zinter MS, Hume JR. Effects of Hematopoietic Cell Transplantation on the Pulmonary Immune Response to Infection. Front Pediatr, 2021,9:634566","journal-title":"Front Pediatr"},{"key":"2936_CR79","doi-asserted-by":"crossref","first-page":"9978837","DOI":"10.1155\/2021\/9978837","volume":"2021","author":"IA Charitos","year":"2021","unstructured":"Charitos IA, Ballini A, Cantore S, et al. Stem Cells: A Historical Review about Biological, Religious, and Ethical Issues. Stem Cells Int, 2021,2021:9978837","journal-title":"Stem Cells Int"},{"issue":"1","key":"2936_CR80","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1038\/s41598-020-62226-1","volume":"10","author":"S van Riet","year":"2020","unstructured":"van Riet S, Ninaber DK, Mikkers HMM, et al. In vitro modelling of alveolar repair at the air-liquid interface using alveolar epithelial cells derived from human induced pluripotent stem cells. Sci Rep, 2020,10(1):5499","journal-title":"Sci Rep"},{"issue":"1","key":"2936_CR81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12964-022-01017-9","volume":"21","author":"E Oveili","year":"2023","unstructured":"Oveili E, Vafaei S, Bazavar H, et al. The potential use of mesenchymal stem cells-derived exosomes as microRNAs delivery systems in different diseases. Cell Commun Signal, 2023,21(1):20","journal-title":"Cell Commun Signal"},{"issue":"9","key":"2936_CR82","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/vaccines9091018","volume":"9","author":"S Daly","year":"2021","unstructured":"Daly S, O\u2019Sullivan A, MacLoughlin R. Cellular Immunotherapy and the Lung. Vaccines (Basel), 2021,9(9):1018","journal-title":"Vaccines (Basel)"},{"issue":"Suppl1","key":"2936_CR83","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcf.2019.11.001","volume":"19","author":"A Paranjapye","year":"2020","unstructured":"Paranjapye A, Ruffin M, Harris A, et al. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. J Cyst Fibros, 2020,19 Suppl 1(Suppl 1):S10\u2013S14","journal-title":"J Cyst Fibros"},{"issue":"8","key":"2936_CR84","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1021\/acsptsci.2c00028","volume":"5","author":"MH Jeong","year":"2022","unstructured":"Jeong MH, Han H, Lagares D, et al. Recent Advances in Molecular Diagnosis of Pulmonary Fibrosis for Precision Medicine. ACS Pharmacol Transl Sci, 2022,5(8):520\u2013538","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"7","key":"2936_CR85","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/stem.3009","volume":"37","author":"J Liang","year":"2019","unstructured":"Liang J, Huang W, Jiang L, et al. Concise Review: Reduction of Adverse Cardiac Scarring Facilitates Pluripotent Stem Cell-Based Therapy for Myocardial Infarction. Stem Cells, 2019,37(7):844\u2013854","journal-title":"Stem Cells"},{"issue":"8","key":"2936_CR86","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/sctm.16-0487","volume":"6","author":"D Driscoll","year":"2017","unstructured":"Driscoll D, Farnia S, Kefalas P, et al. Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access. Stem Cells Transl Med, 2017,6(8):1723\u20131729","journal-title":"Stem Cells Transl Med"},{"key":"2936_CR87","doi-asserted-by":"crossref","first-page":"e05098","DOI":"10.7554\/eLife.05098","volume":"4","author":"BR Dye","year":"2015","unstructured":"Dye BR, Hill DR, Ferguson MA, et al. In vitro generation of human pluripotent stem cell derived lung organoids. Elife, 2015,4:e05098","journal-title":"Elife"},{"issue":"4","key":"2936_CR88","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/ten.2006.12.717","volume":"12","author":"MJ Mondrinos","year":"2006","unstructured":"Mondrinos MJ, Koutzaki S, Jiwanmall E, et al. Engineering three-dimensional pulmonary tissue constructs. Tissue Eng, 2006,12(4):717\u2013728","journal-title":"Tissue Eng"},{"issue":"9","key":"2936_CR89","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nbt.2328","volume":"30","author":"AP Wong","year":"2012","unstructured":"Wong AP, Bear CE, Chin S, et al. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nat Biotechnol, 2012,30(9):876\u2013882","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2936_CR90","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.stem.2012.01.018","volume":"10","author":"H Mou","year":"2012","unstructured":"Mou H, Zhao R, Sherwood R, et al. Generation of multipotent lung and airway progenitors from mouse ESCs and patient-specific cystic fibrosis iPSCs. Cell Stem Cell, 2012,10(4):385\u2013397","journal-title":"Cell Stem Cell"},{"issue":"9","key":"2936_CR91","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.celrep.2015.07.062","volume":"12","author":"AL Firth","year":"2015","unstructured":"Firth AL, Menon T, Parker GS, et al. Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs. Cell Rep, 2015,12(9):1385\u20131390","journal-title":"Cell Rep"},{"issue":"8","key":"2936_CR92","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3275","volume":"33","author":"F Sampaziotis","year":"2015","unstructured":"Sampaziotis F, de Brito MC, Madrigal P, et al. Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat Biotechnol, 2015,33(8):845\u2013852","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2936_CR93","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.chest.2018.10.006","volume":"155","author":"TG Liou","year":"2019","unstructured":"Liou TG. The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease. Chest, 2019,155(3):605\u2013616","journal-title":"Chest"},{"issue":"6","key":"2936_CR94","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.lpm.2017.01.024","volume":"46","author":"I Fajac","year":"2017","unstructured":"Fajac I, Wainwright CE. New treatments targeting the basic defects in cystic fibrosis. Presse Med, 2017,46(6 Pt 2):e165\u2013e175","journal-title":"Presse Med"},{"issue":"1","key":"2936_CR95","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13578-021-00662-w","volume":"11","author":"RA Bandara","year":"2021","unstructured":"Bandara RA, Chen ZR, Hu J. Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy. Cell Biosci, 2021,11(1):145","journal-title":"Cell Biosci"},{"issue":"Suppl1","key":"2936_CR96","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jcf.2019.12.012","volume":"19","author":"A Christopher Boyd","year":"2020","unstructured":"Christopher Boyd A, Guo S, Huang L, et al. New approaches to genetic therapies for cystic fibrosis. J Cyst Fibros, 2020,19 Suppl 1:S54\u2013S59","journal-title":"J Cyst Fibros"},{"issue":"4","key":"2936_CR97","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.trsl.2012.12.005","volume":"161","author":"PB Hackett","year":"2013","unstructured":"Hackett PB, Largaespada DA, Switzer KC, et al. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res, 2013,161(4):265\u2013283","journal-title":"Transl Res"},{"issue":"11","key":"2936_CR98","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/cells10112844","volume":"10","author":"LS Hanssens","year":"2021","unstructured":"Hanssens LS, Duchateau J, Casimir GJ. CFTR Protein: Not Just a Chloride Channel? Cells, 2021,10(11):2844","journal-title":"Cells"},{"issue":"1","key":"2936_CR99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/FPC.0000000000000246","volume":"27","author":"AE Fohner","year":"2017","unstructured":"Fohner AE, McDonagh EM, Clancy JP, et al. PharmGKB: ivacaftor pathway, pharmacokinetics\/pharmacodynamics. Pharmacogenet Genomics, 2017,27(1):39\u201342","journal-title":"Pharmacogenet Genomics"},{"key":"2936_CR100","doi-asserted-by":"crossref","first-page":"i859","DOI":"10.1136\/bmj.i859","volume":"352","author":"BS Quon","year":"2016","unstructured":"Quon BS, Rowe SM. New and emerging targeted therapies for cystic fibrosis. BMJ, 2016,352:i859","journal-title":"BMJ"},{"issue":"1","key":"2936_CR101","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00018-016-2387-7","volume":"74","author":"CM Farinha","year":"2017","unstructured":"Farinha CM, Canato S. From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking. Cell Mol Life Sci, 2017,74(1):39\u201355","journal-title":"Cell Mol Life Sci"},{"key":"2936_CR102","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2020","unstructured":"Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol, 2020,10:1662","journal-title":"Front Pharmacol"},{"issue":"6","key":"2936_CR103","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jcf.2022.09.005","volume":"21","author":"I Sermet-Gaudelus","year":"2022","unstructured":"Sermet-Gaudelus I, Girodon E, Vermeulen F, et al. ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunction. J Cyst Fibros, 2022,21(6):922\u2013936","journal-title":"J Cyst Fibros"},{"issue":"12","key":"2936_CR104","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/diagnostics10121102","volume":"10","author":"FDE De Palma","year":"2020","unstructured":"De Palma FDE, Raia V, Kroemer G, et al. The Multifaceted Roles of MicroRNAs in Cystic Fibrosis. Diagnostics (Basel), 2020,10(12):1102","journal-title":"Diagnostics (Basel)"},{"key":"2936_CR105","first-page":"3542","volume":"42","author":"ME McGarry","year":"2022","unstructured":"McGarry ME, Gibb ER, Oates GR, et al. Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis. Paediatr Respir Rev, 2022,42:3542","journal-title":"Paediatr Respir Rev"},{"issue":"6","key":"2936_CR106","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/genes11060589","volume":"11","author":"V Scotet","year":"2020","unstructured":"Scotet V, L\u2019Hostis C, F\u00e9rec C. The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes (Basel), 2020,11(6):589","journal-title":"Genes (Basel)"},{"issue":"9\u201310","key":"2936_CR107","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1089\/hum.2020.013","volume":"31","author":"Y Tang","year":"2020","unstructured":"Tang Y, Yan Z, Engelhardt JF. Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease. Hum Gene Ther, 2020,31(9\u201310):524\u2013537","journal-title":"Hum Gene Ther"},{"issue":"1","key":"2936_CR108","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther, 2021,6(1):53","journal-title":"Signal Transduct Target Ther"},{"key":"2936_CR109","doi-asserted-by":"crossref","first-page":"119757","DOI":"10.1016\/j.ijpharm.2020.119757","volume":"588","author":"M Sainz-Ramos","year":"2020","unstructured":"Sainz-Ramos M, Villate-Beitia I, Gallego I, et al. Nonviral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality. Int J Pharm, 2020,588:119757","journal-title":"Int J Pharm"},{"key":"2936_CR110","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jconrel.2022.10.061","volume":"352","author":"H Wang","year":"2022","unstructured":"Wang H, Qin L, Zhang X, et al. Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery. J Control Release, 2022,352:970\u2013993","journal-title":"J Control Release"},{"key":"2936_CR111","first-page":"353","volume":"15","author":"M Asmamaw","year":"2021","unstructured":"Asmamaw M, Zawdie B. Mechanism and Applications of CRISPR\/Cas-9-Mediated Genome Editing. Biologics, 2021,15:353\u2013361","journal-title":"Biologics"},{"key":"2936_CR112","doi-asserted-by":"crossref","first-page":"699597","DOI":"10.3389\/fcell.2021.699597","volume":"9","author":"SA Abdelnour","year":"2021","unstructured":"Abdelnour SA, Xie L, Hassanin AA, et al. The Potential of CRISPR\/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases. Front Cell Dev Biol, 2021,9:699597","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"2936_CR113","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.athoracsur.2019.04.030","volume":"108","author":"KB Brothers","year":"2019","unstructured":"Brothers KB, Devereaux M, Sade RM. Bespoke Babies: Genome Editing in Cystic Fibrosis Embryos. Ann Thorac Surg, 2019,108(4):995\u2013999","journal-title":"Ann Thorac Surg"},{"key":"2936_CR114","doi-asserted-by":"crossref","first-page":"825236","DOI":"10.3389\/fgeed.2022.825236","volume":"4","author":"KA Molla","year":"2022","unstructured":"Molla KA, Shih J, Wheatley MS, et al. Predictable NHEJ Insertion and Assessment of HDR Editing Strategies in Plants. Front Genome Ed, 2022,4:825236","journal-title":"Front Genome Ed"},{"key":"2936_CR115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-0716-2301-5_2","volume":"2495","author":"Y Shamshirgaran","year":"2022","unstructured":"Shamshirgaran Y, Liu J, Sumer H, et al. Tools for Efficient Genome Editing; ZFN, TALEN, and CRISPR. Methods Mol Biol, 2022,2495:29\u201346","journal-title":"Methods Mol Biol"},{"key":"2936_CR116","doi-asserted-by":"crossref","first-page":"858870","DOI":"10.1016\/j.omtm.2020.04.005","volume":"17","author":"A Fleischer","year":"2020","unstructured":"Fleischer A, Vallejo-D\u00edez S, Mart\u00edn-Fern\u00e1ndez JM, et al. iPSC-Derived Intestinal Organoids from Cystic Fibrosis Patients Acquire CFTR Activity upon TALEN-Mediated Repair of the p.F508del Mutation. Mol Ther Methods Clin Dev, 2020,17:858870","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"2936_CR117","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","volume":"13","author":"G Schwank","year":"2013","unstructured":"Schwank G, Koo BK, Sasselli V, et al. Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell, 2013,13(6):653\u2013658","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2936_CR118","first-page":"46","volume":"14","author":"W Wang","year":"2013","unstructured":"Wang W, Li W, Ma N, et al. Non-viral gene delivery methods. Curr Pharm Biotechnol, 2013,14(1):46\u201360","journal-title":"Curr Pharm Biotechnol"},{"issue":"11","key":"2936_CR119","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/mtna.2015.37","volume":"4","author":"XH Zhang","year":"2015","unstructured":"Zhang XH, Tee LY, Wang XG, et al. Off-target Effects in CRISPR\/Cas9-mediated Genome Engineering. Mol Ther Nucleic Acids, 2015,4(11):e264","journal-title":"Mol Ther Nucleic Acids"},{"issue":"17","key":"2936_CR120","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1111\/febs.13760","volume":"283","author":"JK Yee","year":"2016","unstructured":"Yee JK. Off-target effects of engineered nucleases. FEBS J, 2016,283(17):3239\u20133248","journal-title":"FEBS J"},{"issue":"9","key":"2936_CR121","doi-asserted-by":"crossref","first-page":"e2000047","DOI":"10.1002\/bies.202000047","volume":"42","author":"A Newman","year":"2020","unstructured":"Newman A, Starrs L, Burgio G. Cas9 Cuts and Consequences; Detecting, Predicting, and Mitigating CRISPR\/Cas9 On- and Off-Target Damage: Techniques for Detecting, Predicting, and Mitigating the On- and off-target Effects of Cas9 Editing. Bioessays, 2020,42(9):e2000047","journal-title":"Bioessays"},{"issue":"6","key":"2936_CR122","doi-asserted-by":"crossref","first-page":"1902312","DOI":"10.1002\/advs.201902312","volume":"7","author":"H Manghwar","year":"2020","unstructured":"Manghwar H, Li B, Ding X, et al. CRISPR\/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off-Target Evaluation, and Strategies to Mitigate Off-Target Effects. Adv Sci (Weinh), 2020,7(6):1902312","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"2936_CR123","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00109-020-01893-z","volume":"98","author":"HA Han","year":"2020","unstructured":"Han HA, Pang JKS, Soh BS. Mitigating off-target effects in CRISPR\/Cas9-mediated in vivo gene editing. J Mol Med (Berl), 2020,98(5):615\u2013632","journal-title":"J Mol Med (Berl)"},{"issue":"7","key":"2936_CR124","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s13238-015-0184-y","volume":"6","author":"J Savulescu","year":"2015","unstructured":"Savulescu J, Pugh J, Douglas T, et al. The moral imperative to continue gene editing research on human embryos. Protein Cell, 2015,6(7):476\u2013479","journal-title":"Protein Cell"},{"key":"2936_CR125","first-page":"595","volume-title":"Designer Babies: The Need for Regulation on the Quest For Perfection","author":"JV Turriziani","year":"2014","unstructured":"Turriziani JV. Designer Babies: The Need for Regulation on the Quest For Perfection. Senton Hall University eRepository, Law School Student Scholarship, 2014, 595. Access on: July 18, 2024. Available on: https:\/\/scholarship.shu.edu\/student_scholarship\/595"},{"issue":"17\u201318","key":"2936_CR126","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1089\/hum.2020.137","volume":"31","author":"A Da Silva Sanchez","year":"2020","unstructured":"Da Silva Sanchez A, Paunovska K, Cristian A, et al. Treating Cystic Fibrosis with mRNA and CRISPR. Hum Gene Ther, 2020,31(17\u201318):940\u2013955","journal-title":"Hum Gene Ther"},{"issue":"1","key":"2936_CR127","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1183\/09031936.00113214","volume":"45","author":"V Viart","year":"2015","unstructured":"Viart V, Bergougnoux A, Bonini J, et al. Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis. Eur Respir J, 2015,45(1):116\u2013128","journal-title":"Eur Respir J"},{"issue":"6","key":"2936_CR128","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1021\/acsami.1c14975","volume":"14","author":"G Conte","year":"2022","unstructured":"Conte G, Costabile G, Baldassi D, et al. Hybrid Lipid\/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference? ACS Appl Mater Interfaces, 2022,14(6):7565\u20137578","journal-title":"ACS Appl Mater Interfaces"},{"key":"2936_CR129","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2014.05.008","volume":"75","author":"I d\u2019Angelo","year":"2014","unstructured":"d\u2019Angelo I, Conte C, La Rotonda MI, et al. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv Drug Deliv Rev, 2014,75:92\u2013111","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2936_CR130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/stem.2402","volume":"35","author":"H Steinle","year":"2017","unstructured":"Steinle H, Behring A, Schlensak C, et al. Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges. Stem Cells, 2017,35(1):68\u201379","journal-title":"Stem Cells"},{"issue":"10","key":"2936_CR131","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6. mRNA-based therapeutics\u2014developing a new class of drugs. Nat Rev Drug Discov, 2014,13(10):759\u2013780","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"2936_CR132","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1089\/hum.2013.2517","volume":"24","author":"MG Katz","year":"2013","unstructured":"Katz MG, Fargnoli AS, Williams RD, et al. Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications. Hum Gene Ther, 2013,24(11):914\u2013927","journal-title":"Hum Gene Ther"},{"issue":"1","key":"2936_CR133","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1535676019899502","volume":"25","author":"S Ghosh","year":"2020","unstructured":"Ghosh S, Brown AM, Jenkins C, et al. Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges. Appl Biosaf, 2020,25(1):7\u201318","journal-title":"Appl Biosaf"},{"issue":"3","key":"2936_CR134","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11095-006-9180-5","volume":"24","author":"W Li","year":"2007","unstructured":"Li W, Szoka FC Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res, 2007,24(3):438\u2013449","journal-title":"Pharm Res"},{"key":"2936_CR135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2020.06.022","volume":"156","author":"N Filipczak","year":"2020","unstructured":"Filipczak N, Pan J, Yalamarty SSK, et al. Recent advancements in liposome technology. Adv Drug Deliv Rev, 2020,156:4\u201322","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"2936_CR136","doi-asserted-by":"crossref","first-page":"103729","DOI":"10.1016\/j.drudis.2023.103729","volume":"28","author":"A Parihar","year":"2023","unstructured":"Parihar A, Prajapati BG, Paliwal H, et al. Advanced pulmonary drug delivery formulations for the treatment of cystic fibrosis. Drug Discov Today, 2023,28(10):103729","journal-title":"Drug Discov Today"},{"issue":"4","key":"2936_CR137","doi-asserted-by":"crossref","first-page":"753","DOI":"10.17344\/acsi.2021.7198","volume":"68","author":"K Balanti\u010d","year":"2021","unstructured":"Balanti\u010d K, Miklav\u010di\u010d D, Kri\u017eaj I, et al. The good and the bad of cell membrane electroporation. Acta Chim Slov, 2021,68(4):753\u2013764","journal-title":"Acta Chim Slov"},{"issue":"5","key":"2936_CR138","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.addr.2004.12.007","volume":"57","author":"S Mehier-Humbert","year":"2005","unstructured":"Mehier-Humbert S, Guy RH. Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev, 2005,57(5):733\u2013753","journal-title":"Adv Drug Deliv Rev"},{"key":"2936_CR139","doi-asserted-by":"crossref","first-page":"1111488","DOI":"10.3389\/fcell.2023.1111488","volume":"11","author":"G Llargu\u00e9s-Sistac","year":"2023","unstructured":"Llargu\u00e9s-Sistac G, Bonjoch L, Castellvi-Bel S. HAP1, a new revolutionary cell model for gene editing using CRISPR-Cas9. Front Cell Dev Biol, 2023,11:1111488","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"2936_CR140","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/03639045.2017.1298122","volume":"43","author":"I Villate-Beitia","year":"2017","unstructured":"Villate-Beitia I, Zarate J, Puras G, et al. Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis. Drug Dev Ind Pharm, 2017,43(7):1071\u20131081","journal-title":"Drug Dev Ind Pharm"},{"issue":"9","key":"2936_CR141","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","volume":"3","author":"EWFW Alton","year":"2015","unstructured":"Alton EWFW, Armstrong DK, Ashby D, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med, 2015,3(9):684\u2013691","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2936_CR142","first-page":"GE01","volume":"9","author":"M Ramamoorth","year":"2015","unstructured":"Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res, 2015,9(1):GE01\u2013GE6","journal-title":"J Clin Diagn Res"},{"issue":"5","key":"2936_CR143","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","volume":"4","author":"CE Thomas","year":"2003","unstructured":"Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet, 2003,4(5):346\u2013358","journal-title":"Nat Rev Genet"},{"issue":"3","key":"2936_CR144","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/1566523054065039","volume":"5","author":"AK Zaiss","year":"2005","unstructured":"Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther, 2005,5(3):323\u2013331","journal-title":"Curr Gene Ther"},{"key":"2936_CR145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pharmthera.2016.11.009","volume":"170","author":"I Fajac","year":"2017","unstructured":"Fajac I, De Boeck K. New horizons for cystic fibrosis treatment. Pharmacol Ther, 2017,170:205\u2013211","journal-title":"Pharmacol Ther"},{"issue":"8","key":"2936_CR146","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/genes13081370","volume":"13","author":"MH Butt","year":"2022","unstructured":"Butt MH, Zaman M, Ahmad A, et al. Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review. Genes (Basel), 2022,13(8):1370","journal-title":"Genes (Basel)"},{"issue":"7573","key":"2936_CR147","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini L. Gene therapy returns to centre stage. Nature, 2015,526(7573):351\u2013360","journal-title":"Nature"},{"issue":"5","key":"2936_CR148","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov, 2019,18(5):358\u2013378","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2936_CR149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"H Li","year":"2020","unstructured":"Li H, Yang Y, Hong W, et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther, 2020,5(1):1","journal-title":"Signal Transduct Target Ther"},{"issue":"S48","key":"2936_CR150","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.23773","volume":"52","author":"J Guimbellot","year":"2017","unstructured":"Guimbellot J, Sharma J, Rowe SM. Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol, 2017,52(S48):S4\u2013S14","journal-title":"Pediatr Pulmonol"},{"issue":"19","key":"2936_CR151","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.3390\/ijms21197353","volume":"21","author":"K Shalaby","year":"2020","unstructured":"Shalaby K, Aouida M, El-Agnaf O. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors. Int J Mol Sci, 2020,21(19):7353","journal-title":"Int J Mol Sci"},{"key":"2936_CR152","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2015.12.012","volume":"240","author":"M Foldvari","year":"2016","unstructured":"Foldvari M, Chen DW, Nafissi N, et al. Non-viral gene therapy: Gains and challenges of non-invasive administration methods. J Control Release, 2016,240:165\u2013190","journal-title":"J Control Release"},{"issue":"1","key":"2936_CR153","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7150\/thno.16911","volume":"7","author":"L Liao","year":"2017","unstructured":"Liao L, Shi B, Chang H, et al. Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy. Theranostics, 2017,7(1):106\u2013116","journal-title":"Theranostics"},{"issue":"2","key":"2936_CR154","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13346-012-0079-x","volume":"3","author":"P Dandawate","year":"2013","unstructured":"Dandawate P, Padhye S, Ahmad A, et al. Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv Transl Res, 2013,3(2):165\u2013182","journal-title":"Drug Deliv Transl Res"},{"issue":"6","key":"2936_CR155","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/med.20009","volume":"24","author":"HS Zhou","year":"2004","unstructured":"Zhou HS, Liu DP, Liang CC. Challenges and strategies: the immune responses in gene therapy. Med Res Rev, 2004,24(6):748\u2013761","journal-title":"Med Res Rev"},{"issue":"3","key":"2936_CR156","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1590\/s1679-45082017rb4024","volume":"15","author":"GAR Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves GAR, Paiva RMA. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo), 2017,15(3):369\u2013375","journal-title":"Einstein (Sao Paulo)"},{"issue":"11","key":"2936_CR157","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/genes9110538","volume":"9","author":"AL Cooney","year":"2018","unstructured":"Cooney AL, McCray PB Jr, Sinn PL. Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes (Basel), 2018,9(11):538","journal-title":"Genes (Basel)"},{"issue":"3","key":"2936_CR158","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/sctm.18-0098","volume":"8","author":"D Hayes Jr","year":"2019","unstructured":"Hayes D Jr, Kopp BT, Hill CL, et al. Cell Therapy for Cystic Fibrosis Lung Disease: Regenerative Basal Cell Amplification. Stem Cells Transl Med, 2019,8(3):225\u2013235","journal-title":"Stem Cells Transl Med"},{"issue":"Suppl2","key":"2936_CR159","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S1569-1993(11)60017-9","volume":"10","author":"M Conese","year":"2011","unstructured":"Conese M, Ascenzioni F, Boyd AC, et al. Gene and cell therapy for cystic fibrosis: from bench to bedside. J Cyst Fibros, 2011,10 Suppl 2:S114\u2013S128","journal-title":"J Cyst Fibros"},{"issue":"4","key":"2936_CR160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/156652307781369119","volume":"7","author":"C Conrad","year":"2007","unstructured":"Conrad C, Gupta R, Mohan H, et al. Genetically engineered stem cells for therapeutic gene delivery. Curr Gene Ther, 2007,7(4):249\u2013260","journal-title":"Curr Gene Ther"},{"issue":"12","key":"2936_CR161","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2010.531257","volume":"10","author":"TJ Myers","year":"2010","unstructured":"Myers TJ, Granero-Molto F, Longobardi L, et al. Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin Biol Ther, 2010,10(12):1663\u20131679","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"2936_CR162","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.stemcr.2015.02.005","volume":"4","author":"AM Crane","year":"2015","unstructured":"Crane AM, Kramer P, Bui JH, et al. Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells. Stem Cell Reports, 2015,4(4):569\u2013577","journal-title":"Stem Cell Reports"},{"issue":"5","key":"2936_CR163","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.stem.2017.10.010","volume":"21","author":"RA Morgan","year":"2017","unstructured":"Morgan RA, Gray D, Lomova A, et al. Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned. Cell Stem Cell, 2017,21(5):574\u2013590","journal-title":"Cell Stem Cell"},{"issue":"6","key":"2936_CR164","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41434-022-00332-7","volume":"30","author":"A McCarron","year":"2023","unstructured":"McCarron A, Cmielewski P, Drysdale V, et al. Effective viral-mediated lung gene therapy: is airway surface preparation necessary?. Gene Ther, 2023,30(6):469\u2013477","journal-title":"Gene Ther"},{"issue":"1","key":"2936_CR165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13287-015-0081-6","volume":"6","author":"YW Lan","year":"2015","unstructured":"Lan YW, Choo KB, Chen CM, et al. Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther, 2015,6(1):97","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"2936_CR166","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1021\/mp2001457","volume":"8","author":"GG Gauglitz","year":"2011","unstructured":"Gauglitz GG, Jeschke MG. Combined gene and stem cell therapy for cutaneous wound healing. Mol Pharm, 2011,8(5):1471\u20131479","journal-title":"Mol Pharm"},{"issue":"17","key":"2936_CR167","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.gt.3302293","volume":"11","author":"B Cao","year":"2004","unstructured":"Cao B, Bruder J, Kovesdi I, et al. Muscle stem cells can act as antigen-presenting cells: implication for gene therapy. Gene Ther, 2004,11(17):1321\u20131330","journal-title":"Gene Ther"},{"issue":"5","key":"2936_CR168","first-page":"546","volume":"12","author":"AU Ahmed","year":"2010","unstructured":"Ahmed AU, Alexiades NG, Lesniak MS. The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther, 2010,12(5):546\u2013552","journal-title":"Curr Opin Mol Ther"},{"key":"2936_CR169","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13287-015-0240-9","volume":"6","author":"J Zhang","year":"2015","unstructured":"Zhang J, Huang X, Wang H, et al. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res Ther, 2015,6:234","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"2936_CR170","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1089\/hum.2017.038","volume":"28","author":"N Brown","year":"2017","unstructured":"Brown N, Song L, Kollu NR, et al. Adeno-Associated Virus Vectors and Stem Cells: Friends or Foes? Hum Gene Ther, 2017,28(6):450\u2013463","journal-title":"Hum Gene Ther"},{"issue":"5","key":"2936_CR171","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/156652312802762518","volume":"12","author":"M Nakanishi","year":"2012","unstructured":"Nakanishi M, Otsu M. Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine. Curr Gene Ther, 2012,12(5):410\u2013416","journal-title":"Curr Gene Ther"},{"issue":"4","key":"2936_CR172","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1165\/rcmb.2012-0406OC","volume":"49","author":"I Mart\u00ednez-Gonz\u00e1lez","year":"2013","unstructured":"Mart\u00ednez-Gonz\u00e1lez I, Roca O, Masclans JR, et al. Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol, 2013,49(4):552\u2013562","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2936_CR173","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.addr.2020.05.002","volume":"168","author":"T Wan","year":"2021","unstructured":"Wan T, Ping Y. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders. Adv Drug Deliv Rev, 2021,168:196\u2013216","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"2936_CR174","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse T, Hu X, Gravina A, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol, 2019,37(3):252\u2013258","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2936_CR175","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.stem.2011.05.012","volume":"8","author":"CE Goldring","year":"2011","unstructured":"Goldring CE, Duffy PA, Benvenisty N, et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell, 2011,8(6):618\u2013628","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2936_CR176","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7150\/ijms.21666","volume":"15","author":"V Volarevic","year":"2018","unstructured":"Volarevic V, Markovic BS, Gazdic M, et al. Ethical and Safety Issues of Stem Cell-Based Therapy. Int J Med Sci, 2018,15(1):36\u201345","journal-title":"Int J Med Sci"},{"issue":"5","key":"2936_CR177","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0015-0282(03)02218-0","volume":"80","author":"L Dawson","year":"2003","unstructured":"Dawson L, Bateman-House AS, Mueller Agnew D, et al. Safety issues in cell-based intervention trials. Fertil Steril, 2003,80(5):1077\u20131085","journal-title":"Fertil Steril"},{"issue":"3","key":"2936_CR178","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/cancers11030345","volume":"11","author":"SM Afify","year":"2019","unstructured":"Afify SM, Seno M. Conversion of Stem Cells to Cancer Stem Cells: Undercurrent of Cancer Initiation. Cancers (Basel), 2019,11(3):345","journal-title":"Cancers (Basel)"},{"issue":"6199","key":"2936_CR179","doi-asserted-by":"crossref","first-page":"1247391","DOI":"10.1126\/science.1247391","volume":"345","author":"IJ Fox","year":"2014","unstructured":"Fox IJ, Daley GQ, Goldman SA, et al. Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science, 2014,345(6199):1247391","journal-title":"Science"},{"issue":"6","key":"2936_CR180","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/biom10060839","volume":"10","author":"BH Yip","year":"2020","unstructured":"Yip BH. Recent Advances in CRISPR\/Cas9 Delivery Strategies. Biomolecules, 2020,10(6):839","journal-title":"Biomolecules"},{"issue":"7","key":"2936_CR181","doi-asserted-by":"crossref","first-page":"e3107","DOI":"10.1002\/jgm.3107","volume":"21","author":"X Xu","year":"2019","unstructured":"Xu X, Wan T, Xin H, et al. Delivery of CRISPR\/Cas9 for therapeutic genome editing. J Gene Med, 2019,21(7):e3107","journal-title":"J Gene Med"},{"issue":"31","key":"2936_CR182","doi-asserted-by":"crossref","first-page":"11730","DOI":"10.1073\/pnas.0603635103","volume":"103","author":"Y Shou","year":"2006","unstructured":"Shou Y, Ma Z, Lu T, et al. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A, 2006,103(31):11730\u201311735","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2936_CR183","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3389\/fphar.2019.00921","volume":"10","author":"C Iglesias-L\u00f3pez","year":"2019","unstructured":"Iglesias-L\u00f3pez C, Agust\u00ed A, Obach M, et al. Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States. Front Pharmacol, 2019,10:921","journal-title":"Front Pharmacol"},{"issue":"6","key":"2936_CR184","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/1467-8519.00307","volume":"16","author":"S Holm","year":"2002","unstructured":"Holm S. Going to the roots of the stem cell controversy. Bioethics, 2002,16(6):493\u2013507","journal-title":"Bioethics"},{"issue":"1","key":"2936_CR185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12967-019-02154-5","volume":"17","author":"L Riva","year":"2019","unstructured":"Riva L, Petrini C. A few ethical issues in translational research for gene and cell therapy. J Transl Med, 2019,17(1):395","journal-title":"J Transl Med"},{"issue":"3","key":"2936_CR186","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/er.2008-0031","volume":"30","author":"B Lo","year":"2009","unstructured":"Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev, 2009,30(3):204\u2013213","journal-title":"Endocr Rev"},{"key":"2936_CR187","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-med-112717-094629","volume":"70","author":"BS Coller","year":"2019","unstructured":"Coller BS. Ethics of Human Genome Editing. Annu Rev Med, 2019,70:289\u2013305","journal-title":"Annu Rev Med"},{"issue":"4","key":"2936_CR188","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1748-720X.1995.tb01373.x","volume":"23","author":"KH Rothenberg","year":"1995","unstructured":"Rothenberg KH. Genetic information and health insurance: state legislative approaches. J Law Med Ethics, 1995,23(4):312\u2013319","journal-title":"J Law Med Ethics"},{"issue":"40","key":"2936_CR189","doi-asserted-by":"crossref","first-page":"eabo0522","DOI":"10.1126\/sciadv.abo0522","volume":"8","author":"AS Piotrowski-Daspit","year":"2022","unstructured":"Piotrowski-Daspit AS, Barone C, Lin CY, et al. In vivo correction of cystic fibrosis mediated by PNA nanoparticles. Sci Adv, 2022,8(40):eabo0522","journal-title":"Sci Adv"},{"issue":"6701","key":"2936_CR190","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1126\/science.adk9428","volume":"384","author":"Y Sun","year":"2024","unstructured":"Sun Y, Chatterjee S, Lian X, et al. In vivo editing of lung stem cells for durable gene correction in mice. Science, 2024,384(6701):1196\u20131202","journal-title":"Science"},{"issue":"1","key":"2936_CR191","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1038\/s41467-023-43904-w","volume":"14","author":"K Kulhankova","year":"2023","unstructured":"Kulhankova K, Traore S, Cheng X, et al. Shuttle peptide delivers base editor RNPs to rhesus monkey airway epithelial cells in vivo. Nat Commun, 2023,14(1):8051","journal-title":"Nat Commun"},{"issue":"12","key":"2936_CR192","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/cells12121555","volume":"12","author":"G Wang","year":"2023","unstructured":"Wang G. Genome Editing for Cystic Fibrosis. Cells, 2023,12(12):1555","journal-title":"Cells"},{"issue":"1","key":"2936_CR193","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","volume":"14","author":"L Allen","year":"2023","unstructured":"Allen L, Allen L, Carr SB, et al. Future therapies for cystic fibrosis. Nat Commun, 2023,14(1):693","journal-title":"Nat Commun"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-024-2936-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-024-2936-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-024-2936-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T12:24:03Z","timestamp":1734956643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-024-2936-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":193,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2936"],"URL":"https:\/\/doi.org\/10.1007\/s11596-024-2936-5","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}